Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 10567X101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
|
13.5% |
9/10/2026
Event 9/8/2026
|
|
| Orbimed Advisors LLC | 13.5% | ||
| OrbiMed Capital GP IX LLC | 13.2% | ||
| OrbiMed Genesis GP LLC | 0.3% | ||
|
AH Bio Fund IV, L.P.
13D
|
11.4% |
8/14/2026
Event 8/7/2026
|
|
| AH Bio Fund IV, L.P. | 11.4% | ||
| AH Equity Partners Bio IV, L.L.C. | 11.4% | ||
| Marc L. Andreessen | 11.4% | ||
| Benjamin A. Horowitz | 11.4% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
5.5% |
8/14/2026
Event 8/7/2026
|
|
| Frazier Life Sciences Public Fund, L.P. | 5.5% | ||
| FHMLSP, L.P. | 5.5% | ||
| FHMLSP, L.L.C. | 5.5% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| Frazier Life Sciences XII, L.P. | 0.1% | ||
| FHMLS XII, L.P. | 0.1% | ||
| FHMLS XII, L.L.C. | 0.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 36.1 k | $730 k |